Epitopea Secures $31m in Pre-Series A Funding with Osborne Clarke's Guidance
Deal News | Feb 24, 2025 | Osborne Clarke
International legal practice Osborne Clarke has provided legal advisory services to Epitopea, a cancer immunotherapeutics firm focused on developing RNA-based immunotherapies. This strategic guidance helped Epitopea successfully secure a pre-Series A financing amounting to $31 million. The funding will support Epitopea's efforts in making cancer treatments more accessible, leveraging their expertise in RNA-based solutions. This investment signifies a substantial vote of confidence from investors in the growth and potential of Epitopea's innovative therapeutic solutions.
Sectors
- Biotechnology
- Legal Services
Geography
- Transatlantic – Epitopea is described as a transatlantic company, indicating operations and potential markets in both the United States and Europe.
Industry
- Biotechnology – The article discusses Epitopea, a company involved in developing RNA-based cancer immunotherapies, which is part of the biotechnology industry.
- Legal Services – Osborne Clarke's role as a legal advisor in the funding deal places this article also within the legal services industry.
Financials
- 31,000,000 – The amount raised by Epitopea in their pre-Series A financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Epitopea | Target Company | Company | A cancer immunotherapeutics company developing RNA-based treatments. |
| Osborne Clarke | Legal Advisor | Company | An international legal practice that advised Epitopea on their pre-Series A financing. |